Life Biosciences Appoints Dr. Michael Ringel as Chief Operating Officer
BOSTON, January 27, 2025 – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced the appointment of Michael Ringel, Ph.D., J.D., as Chief Operating Officer.
“Michael is a recognized leader with decades of experience driving innovation and strategy in the biotech and pharmaceutical sectors and has committed a substantial amount of his career to the rapidly growing aging and healthspan sectors,” said Jerry McLaughlin, Chief Executive Officer of Life Bio. “His extraordinary strategic acumen, operational expertise, and industry insight will be critical to Life Bio as we prepare to advance the first ever partial epigenetic reprogramming candidate into the clinic this year.”
Amit Shashank, Chief Administrative Officer and General Counsel at Life Bio, added, “Moving our lead program into human clinical trials this year is a tremendous watershed moment for Life Bio, and one that is essential in validating our unique approach. While Michael’s leadership will be pivotal in successfully advancing this program, his extensive leadership as a pioneer in this space will be crucial as we maximize the breadth and depth of what our technology offers across multiple therapeutic modalities and lead to the development of transformative medicines for patients facing a range of age-related diseases.”
“As an advisor to Life Bio, I’ve had the opportunity to see first-hand the strength of the company’s partial epigenetic reprogramming platform and the emerging therapeutic pipeline founded on it,” stated Dr. Ringel. “I’m convinced that the platform holds immense promise long-term to reshape the future of aging and extend healthy human lifespan. In the near-term we will have clinical-stage assets addressing serious age-related diseases with the potential to greatly improve care for patients. I’m excited to roll up my sleeves and work with Life Bio’s experienced and talented team to ensure flawless operational execution against this potential.”
Before joining Life Biosciences, Dr. Ringel served as Managing Director and Senior Partner at Boston Consulting Group (BCG), where he advised biotech and pharmaceutical clients on R&D strategy, portfolio optimization, and organizational design. As BCG’s global leader for innovation analytics and research and product development, Dr. Ringel has been a noted contributor to industry journals, and has extensive experience in M&A, licensing and
partnerships, and corporate strategy. Dr. Ringel serves on the boards of Hevolution Foundation U.S. and the American Federation for Aging Research.
Dr. Ringel holds a B.A. in Biology from Princeton University, a Ph.D. in Biology from Imperial College, and a J.D. from Harvard Law School.
About Life Biosciences
Life Bio is a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. The company’s proprietary partial epigenetic reprogramming platform utilizes three transcription factors—Oct4, Sox2, and Klf4—to restore older and damaged cells to a younger state. This innovative approach targets a root cause of aging at the epigenetic level, thereby offering the potential to address a wide range of age-related diseases with significant unmet medical needs. Life Bio’s lead program, ER-100, is being developed as a gene therapy for optic neuropathies with plans to enter the clinic in 2025. Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. For more information, visit www.lifebiosciences.com or follow Life Bio on Twitter (X) and LinkedIn.
Media Contact
Michael Rubenstein
LifeSci Communications
mrubenstein@lifescicomms.com
+1 646-386-1613
Life Biosciences Presents at AAO Highlighting Progress of Nonhuman Primate Studies Evaluating Partial Epigenetic Reprogramming to Restore Visual Function
Data replicate and expand upon the potential of ER-100 to improve retinal ganglion cell function and restore visual function in a nonhuman primate model of nonarteritic anterior ischemic optic neuropathy (NAION)
BOSTON, October 21, 2024 – Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, today announced new data presented at the 2024 American Association of Ophthalmology (AAO) Annual Meeting that took place in Chicago, Illinois from October 18-21, 2024. Results replicate previously reported nonhuman primate (NHP) data and further expand our knowledge on dosing and timing of treatment.
ER-100, a novel partial epigenetic reprogramming gene therapy containing Oct-4, Sox-2 and Klf-4 (OSK), was administered via a single intravitreal injection along with daily systemic doxycycline to NHPs with a NAION-like injury. Immunohistochemistry confirmed expression of each transcription factor (Oct-4, Sox-2 and Klf-4) in discrete cells in the perifoveal regions in ER-100 treated NHPs relative to vehicle. Furthermore, ER-100 significantly reduced deficits in pattern electroretinogram and axon density measures when administered in both prevention and rescue paradigms. Collectively, these results demonstrate that ER-100 successfully targets retinal ganglion cells and reduces the loss of visual function in a NHP model of NAION. Life Bio remains on track to initiate the first human clinical study evaluating ER-100 for optic neuropathies in the second half of 2025.
“Partial epigenetic reprogramming has the potential to restore visual function for those with optic neuropathies such as NAION and glaucoma,” said Sharon Rosenzweig-Lipson, Ph.D., Chief Scientific Officer of Life Bio. “The data shared today replicate and build upon our understanding of the dosing of ER-100 and the timing of the treatment window relative to the onset of NAION-related damage. We look forward to advancing this program toward human clinical trials next year for patients affected by these age-related optic neuropathies.”
About Life Biosciences
Life Biosciences is a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimately restore health for patients. The company is focusing on two platforms targeting key mechanisms underlying aging biology, epigenetic reprogramming and chaperone-mediated autophagy, to restore cells to a more youthful state. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com or follow us on Twitter and LinkedIn.
Media Contact
Kristin Politi, Ph.D.
LifeSci Communications
kpoliti@lifescicomms.com
(646) 876-4783
Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development
Boston, MA, May 23, 2023 – Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimately restore health for patients, today announced the appointment of Ming Yang, Ph.D., as Senior Vice President of Research and Development. Dr. Yang will be responsible for overseeing the company’s research and development efforts and advancing its pipeline of cellular rejuvenation candidates.
“We are delighted to welcome Dr. Yang to the Life Bio team. He brings over 20 years of experience in translational biomedical research, with expertise in research and development from drug discovery to clinical development across a range of indications including ophthalmology – all of which will be critical in the next phase of our corporate development,” said Sharon Rosenzweig-Lipson, Ph.D., Chief Scientific Officer of Life Bio. “We look forward to working with him as we continue to develop innovative therapies for age-related diseases.”
Dr. Yang has a track record of building and leading multifunctional R&D teams and advancing early-stage research programs to clinical stage. Prior to joining Life Bio, he served as Senior Vice President of Research and Development at Graybug Vision, Inc., now CalciMedica Inc. (NASDAQ: CALC), where he led all R&D efforts to advance ophthalmic pipeline programs to clinical development and oversaw the operations of the company’s research center. Prior to Graybug, Dr. Yang conducted research to develop sustained-release protein therapeutics at Genentech, Inc.
“The work that Life Biosciences is doing has the potential to make a meaningful impact on the way we target and treat age-related diseases,” said Dr. Yang. “I look forward to working closely with the talented R&D team and the incredible leadership team to advance our pipeline of novel cellular rejuvenation therapies to restore cells to a more youthful state and bring new treatments to patients.”
Dr. Yang received his doctoral degree in biomedical engineering from Johns Hopkins School of Medicine and his bachelor of engineering in materials science and engineering from Tsinghua University. He has over 20 issued United States patents and has invented platform technologies that led to two FDA-approved drugs.
About Life Biosciences
Life Biosciences is a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimately restore health for patients. The company is focusing on two platforms targeting key mechanisms underlying aging biology, epigenetic reprogramming and chaperone-mediated autophagy, to restore cells to a more youthful state. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com or follow us on Twitter and LinkedIn.
Media Contact
Justin Perry, Ph.D.
LifeSci Communications
jperry@lifescicomms.com
Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging- Related Diseases
Forge to provide cGMP manufacturing and development services for Life Biosciences’ novel adeno-associated virus (AAV) gene therapy platform for aging-related diseases, including in ophthalmic indications
BOSTON AND COLUMBUS, Ohio, May 8, 2023 – Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, and Forge Biologics (“Forge”), a genetic medicines manufacturing organization, today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.
“Life Bio is an emerging leader in the development of novel therapies for aging-related diseases, and we are thrilled to serve as their cGMP manufacturing partner to help advance the manufacturing of AAV for their innovative cellular rejuvenation technology, which has the potential to benefit millions of aging patients worldwide,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge.
Through this partnership, Forge will provide adeno-associated virus (AAV) process development, toxicology, cGMP manufacturing, and analytical services to Life Bio. The company will utilize Forge’s platform processes including its proprietary HEK293 suspension Ignition Cells™ and pEMBR™ adenovirus helper plasmid. All development and AAV manufacturing activities will occur at the Hearth, Forge’s 200,000 square foot gene therapy facility in Columbus, Ohio.
“We are delighted to be working with the Forge team, whose expertise in gene therapy manufacturing is unmatched,” said Jerry McLaughlin, Chief Executive Officer of Life Biosciences. “We believe we’re on the cusp of revolutionizing medicine with our cellular rejuvenation capabilities across a range of aging-related diseases, including ophthalmic disorders that involve retinal ganglion cell dysfunction. We are confident our partnership with Forge will have a tremendous impact on our ability to enhance the speed and quality with which we can manufacture our therapeutic candidates as we progress toward the first human clinical trials and continue to develop treatments to reverse diseases of aging by restoring cells to a more youthful state.”
About Life Biosciences
Life Biosciences is a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimately restore health for patients. The company is focusing on two platforms targeting key mechanisms underlying aging biology, epigenetic reprogramming and chaperone-mediated autophagy, to restore cells to a more youthful state. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit lifebiosciences.com or follow us on Twitter and LinkedIn.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life-changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV manufacturing and hosts scalable, end-to-end manufacturing services. Offerings include process and analytical development, plasmid DNA manufacturing, viral vector manufacturing, final fill, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.
Media Inquiries – Forge Biologics
Marina Corleto
Associate Director, Marketing and Communications
media@forgebiologics.com
Media Inquiries – Life Biosciences
Justin Perry, Ph.D.
Account Executive, LifeSci Communications
jperry@lifescicomms.com
Client Development – Forge Biologics
Taleen Barsoumian
Vice President, Client Development
CD@forgebiologics.com
Life Biosciences Presents Groundbreaking Data at ARVO Demonstrating Restoration of Visual Function in Nonhuman Primates
Data in a nonhuman primate model of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) demonstrates the ability to restore visual function after delivery of a novel gene therapy
BOSTON, April 23, 2023 — Life Biosciences, a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, today announced preclinical data in nonhuman primates (NHP) for its novel gene therapy candidate which uses a partial epigenetic reprogramming approach to restore visual function.
This approach has been shown to reverse aging, improve vision, and extend lifespan in mice, but whether epigenetic reprogramming would work in primates was not known. Today, researchers at Life Bio and academic researchers, including Dr. Bruce Ksander and Dr. David Sinclair, reported that Life Bio’s therapy significantly restored visual function in an NHP model of non-arteritic anterior ischemic optic neuropathy (NAION), a disorder similar to a stroke of the eye that is characterized by painless yet sudden loss of vision. The data, presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 conference in New Orleans, LA, represents an important step forward toward enabling human clinical trials to potentially treat a variety of ophthalmic disorders and other diseases of aging.
Life Bio’s lead platform reprograms the epigenome of older animals to resemble that of younger animals via expression of three Yamanaka factors, Oct4, Sox2, and Klf4, collectively known as OSK. The approach partially reprograms cells to resemble a more youthful state while retaining their original cellular identity. Previous data from Life Bio and academic researchers, which were also presented at ARVO 2023, have shown that treatment with OSK reverses retinal aging and restores vision in old mice in a mouse model of glaucoma. Now, with the data presented today at ARVO, the company has demonstrated restoration of visual function and increased nerve axon survival in an NHP model that mimics human NAION deficits in retinal ganglion cells. Key data highlights include the following:
- Laser-induced damage to the eyes of NHPs showed a reduction in the key ophthalmic measures that are typically seen in humans with NAION, including pattern electroretinogram (pERG) signals, optical coherence tomography (OCT), retinal nerve fiber layer (RNFL) thickness, and number of surviving optic nerve axons.
- NHPs received an intravitreal (in-eye) injection of doxycycline-inducible OSK viruses or vehicle one day after laser damage. Doxycycline was administered systemically until the end of the study.
- When eyes were treated with OSK after laser damage, OSK significantly restored pERG responses compared to controls, consistent with restoration of vision.
- OSK also significantly improved the number of healthy axon bundles compared to controls.
“NAION is the most common cause of acute optic neuropathy in people over 50, but currently has no effective treatment. The data we are presenting here show, for the very first time, that treatment with OSK can lead to significant recovery in affected visual function in an NHP model of NAION, the gold standard translational model. That potential unlocks new opportunities for cellular rejuvenation, not just in NAION but in other ophthalmic diseases that occur as a result of retinal ganglion cell dysfunction as we age,” said Bruce Ksander, PhD, Associate Professor of Ophthalmology and Co-Director of the Ocular Oncology Center of Excellence at Harvard Medical School, and lead presenter of the study at the ARVO conference.
Sharon Rosenzweig-Lipson, PhD, Chief Scientific Officer of Life Bio, added, “We are delighted to present this truly groundbreaking data, which further validate Life Bio’s innovative approach to cellular rejuvenation. This approach has implications far beyond NAION and even the vision field, and we are pleased to share data that support the continued development of our scientific platform to address diseases of aging and restore human health.”
Life Bio is advancing its cellular rejuvenation capabilities across a range of aging-related diseases, including additional ophthalmic and neurodegenerative indications. The data being presented at ARVO builds on previous findings from Dr. David Sinclair’s and Dr. Bruce Ksander’s labs at Harvard Medical School showing that OSK can reverse aging in mice.
Dr. Sinclair, Co-Founder of Life Bio, Member of the company’s Board of Directors, Professor in the Department of Genetics and Co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School, and coauthor on the study, said, “Demonstrating rejuvenation in nonhuman primates is a major step forward in advancing cellular rejuvenation as a way of treating both common and rare diseases in the eye and potentially other tissues. What we’ve learned in NHPs has important ramifications for research on reversing aging and is likely to be highly translational to humans. This data moves us an important step closer to the first clinical trials of how cellular rejuvenation technology could treat aging-related diseases.”
About Life Biosciences
Life Biosciences is a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimately restore health for patients. The company is focusing on two platforms targeting key mechanisms underlying aging biology, epigenetic reprogramming and chaperone-mediated autophagy, to restore cells to a more youthful state. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit lifebiosciences.com or follow us on Twitter and LinkedIn.
About OSK
Life Bio’s lead platform, OSK, was invented in the lab of Professor David Sinclair, AO, PhD, Co-Founder of Life Bio, Member of the company’s Board of Directors, and Professor in the Department of Genetics and Co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. The partial reprogramming technology was in-licensed by Life Bio from Harvard University. The technology was based on Dr. Sinclair’s Information Theory of Aging and works by reprogramming the epigenome of older animals to resemble that of younger animals via expression of three Yamanaka factors, Oct4, Sox2, and Klf4, collectively known as OSK. The approach partially reprograms cells to resemble a more youthful state while retaining their original cellular identity.
Media Contact
Gwendolyn Schanker
LifeSci Communications
gschanker@lifescicomms.com
Life Biosciences Appoints Sharon Rosenzweig-Lipson, PhD as Chief Scientific Officer
Dr. Rosenzweig-Lipson brings decades of experience in R&D strategy and clinical development as Life Biosciences advances therapeutics that target the biology of aging
BOSTON, February 13, 2023 – Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced the appointment of Sharon Rosenzweig-Lipson, PhD as Chief Scientific Officer. At Life Biosciences, she will be responsible for leading the company’s scientific research and development efforts built on the epigenetic reprogramming science of Dr. David Sinclair and the chaperone-mediated autophagy discoveries of Dr. Ana Maria Cuervo.
“Dr. Rosenzweig-Lipson brings great scientific and strategic leadership to Life Biosciences,” said Jerry McLaughlin, Chief Executive Officer at Life Biosciences. “Sharon has been serving as a consultant to Life since early 2021 and has helped to create strong processes to accelerate our drug discovery and development. Her impressive background and accomplishments in both preclinical and clinical development will continue to be invaluable to us as we progress our therapies toward the clinic. It is a pleasure to officially welcome her to the team.”
“I am thrilled to be joining Life Biosciences to revolutionize the treatment of a wide-range of age-related disorders,” said Dr. Rosenzweig-Lipson. “I look forward to collaborating with the strong mission-driven team at Life Biosciences and its outstanding scientific collaborators.”
Dr. Rosenzweig-Lipson holds significant expertise in screening strategies, in vivo models, translation, and clinical development strategy with more than three decades of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry and in biotech. Her career in big pharma includes American Cyanamid, American Home Products, Wyeth, and Pfizer. Most recently, as head of R&D, Dr. Rosenzweig-Lipson led the clinical development of AgeneBio’s lead asset through Phase 2B trials as well as the company’s preclinical development programs. Dr. Rosenzweig-Lipson earned her BA in the biological basis of behavior from the University of Pennsylvania and her PhD in behavioral neuroscience from Harvard University.
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on two platforms targeting key mechanisms underlying aging biology: epigenetic reprogramming to restore cellular function to a more youthful state and chaperone-mediated autophagy to reverse the age-related decline in the body’s ability to recycle unwanted proteins. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
Media
media@lifebiosciences.com
Life Biosciences CEO Jerry McLaughlin to Speak at Roadmap to Healthy Longevity International Summit
BOSTON, February 9, 2023 — Life Biosciences, a pioneering biotech company developing therapeutics that target the biology of aging, today announced that Jerry McLaughlin, Chief Executive Officer, will speak at the Roadmap to Healthy Longevity: Enabling Healthier, Longer Lives in the GCC conference February 19, 2023, in Riyadh, Saudi Arabia. McLaughlin will participate on a panel entitled “Meet the Healthy Longevity Innovators.”
“Our scientific team at Life Biosciences is at the cutting edge of developing novel therapies based on exciting advances in age-related science,” said McLaughlin. “I’m proud to speak at this important international conference to discuss developments in the bourgeoning healthspan space that are rooted in innovative science as well as to share more about Life’s scientific progress to date and its robust pipeline.”
About the Conference
Jointly organized by the US National Academy of Medicine (NAM), Hevolution Foundation, and the King Abdullah International Medical Research Center (KAIMRC), the event will gather leaders from across the longevity ecosystem to discuss the state of longevity and healthy lifespan in the Gulf Region and an envisioned world with healthy longevity by 2050.
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on two platforms targeting key mechanisms underlying aging biology: epigenetic reprogramming to restore cellular function to a more youthful state and chaperone-mediated autophagy to reverse the age-related decline in the body’s ability to recycle unwanted proteins. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
Life Biosciences to Present at Longevity Leaders World Congress 2022
BOSTON, April 14, 2022 — Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced that Jerry McLaughlin, Chief Executive Officer, will speak at the fourth annual Longevity Leaders World Congress being held on April 26-27, 2022, in London, UK.
Mr. McLaughlin will deliver a presentation on April 26 at 11:10 BST titled, “Targeting Mechanisms Underlying the Biology of Aging to Treat and Reverse Disease.”
“Life Biosciences is truly at the forefront of developing novel therapies based on exciting advances in age-related science,” says Mr. McLaughlin. “I’m delighted to have the opportunity to share more about our work and progress here at Life Biosciences and discuss ways to work with pioneers in the field to move our industry forward.”
The Longevity Leaders World Congress, hosted by LSX, brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies, and commercialization to target age-related diseases. Those interested in attending the conference may register here.
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
Media
media@lifebiosciences.com
Investor Relations
Bill Sullivan
IR@lifebiosciences.com
Life Biosciences, Leading Developer of Therapeutics for Aging-Related Diseases, Completes $82 Million Series C Financing Round
Announces Bill Sullivan as Chief Financial Officer
BOSTON, Jan. 5, 2022 — Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced the completion of a Series C financing of $82 million led by Alpha Wave Ventures. Senior management and founders invested in the Series C financing alongside longevity-oriented funds, seasoned investors, and experienced biotechnology scientists/entrepreneurs. Since its founding, Life Biosciences has raised over $158 million.
“Our three platforms are based on seminal research demonstrating that aging biology can be modified therapeutically. The Series C funding enables us to accelerate development of our innovative therapies for multiple aging-related conditions, and we expect to initiate first-in-human studies for our first drug candidate possibly as early as the end of 2022,” said Chief Executive Officer Jerry McLaughlin. “We appreciate the support of both our new and existing investors as we advance the company to its next stage of development. Life Biosciences’ experienced management team is committed to bringing potentially pioneering science to the service of humanity.”
Proceeds from the Series C financing will be used to accelerate research and development activities in the company’s three platforms that target fundamental biological mechanisms contributing to aging. The mitochondrial uncoupling platform is developing oral small molecules that are designed to increase metabolic rate and decrease fat accumulation in models of obesity and NASH. The chaperone-mediated autophagy (CMA) platform is developing oral small molecules that are designed to activate CMA and thereby remove unwanted proteins that accumulate during aging and contribute to multiple aging-related diseases including neurodegenerative diseases. The epigenetic reprogramming platform is developing therapies that are designed to induce the expression of three Yamanaka factors to reprogram the epigenome of cells to a younger state and thereby restore cellular function across a wide range of diseases such as glaucoma.
Commenting on the investment, Alpha Wave Global Chairman Rick Gerson added, “We are impressed by the groundbreaking science that has been published in leading and recently peer-reviewed journals like Nature and Cell by the company’s co-founder and director David Sinclair and other founder scientists such as Dr. Ana Maria Cuervo. Their foundational science could revolutionize how we develop therapies for aging-related conditions. We are excited to invest in this emerging field and believe that Life Biosciences’ experienced management team and exceptional science has the potential to unlock a new wave of therapies across their multiple platforms.”
In addition, Life Biosciences announces the appointment of Bill Sullivan as Chief Financial Officer. Bill brings more than 25 years of experience in corporate finance, strategic transactions, fundraising, and investor relations. He served as Chief Financial Officer and Treasurer at Applied Genetic Technologies Corporation, a publicly traded gene therapy company, where he led multiple financings and core business and finance functions. Prior to AGTC, he worked at Merrimack Pharmaceuticals, Inc. for ten years and held a variety of important leadership positions including Chief Financial Officer.
“It’s an honor to join the Life Biosciences team as the company pursues tremendous growth opportunities where aging biology has a clear link to disease pathogenesis,” said Mr. Sullivan. “I’m energized by both the people and strong science at the company and look forward to working together with the management team to drive the next phase of growth.”
“I couldn’t be more delighted by the progress made by the Life Biosciences’ team under Jerry’s leadership to sharpen its focus on developing therapeutics on a platform-oriented approach. In my opinion, Life Biosciences is on the cusp of revolutionizing medicine for aging-related diseases globally,” said Executive Chairman Dr. Mehmood Khan.
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
About Alpha Wave Global
Alpha Wave is a global investment company with offices in New York, Miami, London, Abu Dhabi, Tel Aviv, and Bangalore. Its flagship global venture and growth fund, Alpha Wave Ventures, aims to invest in best-in-class venture and growth-stage companies and endeavors to be helpful long-term partners to the founders and management teams. Alpha Wave manages a variety of investment partnerships that cover a number of asset classes, themes, and geographies. For more information, please visit www.alphawaveglobal.com.
Media Contact
Maggie Farrand
media@lifebiosciences.com
Life Biosciences Receives Translational Research Funding from Alzheimer’s Drug Discovery Foundation
BOSTON, Sept. 28, 2021 — Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced translational research funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of chaperone-mediated autophagy (CMA) activators for the treatment of Alzheimer’s disease and other neurodegenerative diseases.
Chaperone-mediated autophagy removes unwanted soluble proteins from cells. CMA activity declines with age due in part to decreased expression of LAMP2A, a key protein regulating CMA activity. The age-related decline of CMA leads to an accumulation of insoluble proteins that disrupt cellular function in age-related diseases such as Alzheimer’s disease.
In groundbreaking work published in the peer-reviewed journal Cell in April 2021, Professor at the Albert Einstein College of Medicine and Life Biosciences founder scientist Ana Maria Cuervo, MD, PhD demonstrated the benefit of the CMA-activator platform in two mouse models of Alzheimer’s disease. In both models, oral doses of CMA-activator compounds led to improvements in memory, depression, and anxiety. Life Biosciences has an exclusive license from Albert Einstein College of Medicine for this underlying technology and will continue this research by evaluating CMA-activator compounds for key early attributes needed in Alzheimer’s disease drug development.
“We are pleased to have received this translational research funding from the ADDF, which further validates the potential of our CMA platform to treat devastating diseases such as Alzheimer’s,” said Jerry McLaughlin, Chief Executive Officer of Life Biosciences. “Our preclinical work to date has demonstrated that CMA activation may be a viable therapeutic strategy in halting the progression of age-related neurodegenerative disorders and ultimately increase healthy human lifespan. We look forward to advancing this platform towards the clinic with the support of the ADDF.”
“Life Biosciences’ innovative pathway holds exciting promise for the potential treatment and prevention of Alzheimer’s disease,” said Howard Fillit, MD, Founding Executive Director and Chief Science Officer of the ADDF. “After substantial scientific review, we believe that CMA could offer a unique approach to Alzheimer’s disease, and we look forward to partnering with Life Biosciences as it advances its important research towards the clinic.”
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to developing novel therapies to extend healthy human lifespan. The Company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
About the Alzheimer’s Drug Discovery Foundation
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s and related dementias, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded more than $168 million to fund over 650 Alzheimer’s drug discovery and biomarker programs and clinical trials in 19 countries. To learn more, please visit: http://www.alzdiscovery.org/.
Media Contact
Maggie Farrand
media@lifebiosciences.com